

- 2 -

Ser. No.09/954,571

IN THE CLAIMS

1. (once amended) A method for delivering a therapeutic dose of a gene expression cassette in a fluid selectively to heart for sustained expression comprising steps of:
 - (a) increasing dwell time of fluid in a targeted area by induction of complete or near-complete transient cardiac arrest,
 - (b) administration of a vascular permeablizing agent, and
 - (c) administration of a viral vector containing a gene expression cassette of interest.
2. (once amended) A method as in claim 1, wherein the dwell time is further increased by the induction of hypothermia.
3. (once amended) A method as in claim 1, wherein the dwell time is further increased by isolation of the heart from systemic circulation.
4. (once amended) A method as in claim 1, wherein the dwell time is further increased by induction of hypothermia and isolation of the heart from systemic circulation.
5. (cancelled)
6. (once amended) A method as in claim 1, wherein dwell time is further increased by induction of reversible bradycardia.
7. (original) A method as in claim 1, wherein the vascular permeablizing agent is histamine, substance P or serotonin.
8. (original) A method as in claim 1, wherein at least one bolus of virus is administered.

[H:\Colleen\6627-CHIEMPA0123.ELEYCHIE03.112.frm]

- 3 -

Ser. No.09/954,571

9. (original) A method as in claim 1, wherein the viral vector is an adenoviral vector.
10. (original) A method as in claim 9, wherein the adenoviral vector contains a strong promoter.
11. (original) A method as in claim 10, wherein the strong promoter is a cytomegalovirus (CMV) promoter.
12. (original) A method as in claim 10, wherein the strong promoter is a Rous sarcoma virus (RSV) promoter.
13. (original) A method as in claim 9, wherein the adenoviral vector contains enhancer elements.
14. (original) A method as in claim 13, wherein the enhancer is a cytomegalovirus (CMV) enhancer.
15. (original) A method as in claim 13, wherein the enhancer is a Rous sarcoma virus (RSV) enhancer.
16. A method as in claim 1, wherein the viral vector is an adenovirus-associated viral (AAV) vector.
17. (original) A method as in claim 16, wherein the AAV vector contains a strong promoter.
18. (original) A method as in claim 17, wherein the strong promoter is a

[H:\Colleen\6627-CHIEN\PA0123.ELEYCHIE03.112.frm]

- 4 -

Ser. No.09/954,571

cytomegalovirus (CMV) promoter.

19. (original) A method as in claim 16, wherein the strong promoter is a Rous sarcoma virus (RSV) promoter.

20. (original) A method as in claim 9, wherein the AAV vector contains enhancer elements.

21. (original) A method as in claim 20, wherein the enhancer is a cytomegalovirus (CMV) enhancer.

22. (original) A method as in claim 20, wherein the enhancer is a Rous sarcoma virus (RSV) enhancer.

23-30.(cancelled)

31. (original) A method as in claim 1, wherein the gene of interest is a gene fragment.

32-40.(cancelled)